Comparative Pharmacology
Head-to-head clinical analysis: DIPHEN versus PROMETH PLAIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHEN versus PROMETH PLAIN.
DIPHEN vs PROMETH PLAIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenhydramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors. It also exhibits anticholinergic, sedative, antiemetic, and local anesthetic effects.
Antagonist at histamine H1 receptors; also exhibits anticholinergic, antiemetic, and sedative effects.
50 mg IV/IM every 4 hours as needed for nausea/vomiting; 25-50 mg PO every 4-6 hours as needed for nausea/vomiting or motion sickness; 25 mg PO 3-4 times daily for vertigo; 15.6-25 mg IM/IV for antiemetic in surgery; maximum 300 mg/day.
12.5-25 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Clinical Note
moderateDiphenoxylate + Torasemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide."
Clinical Note
moderateDiphenoxylate + Etacrynic acid
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid."
Clinical Note
moderateDiphenoxylate + Furosemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide."
Clinical Note
moderateTerminal elimination half-life is 22–72 hours (mean 30–40 hours); increases with hepatic disease or enzyme inhibitors.
Terminal elimination half-life is 10-14 hours in adults; may be prolonged in elderly or hepatic impairment.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for ~70% of eliminated drug; biliary/fecal excretion accounts for ~30%.
Primarily renal (approximately 70%) as metabolites and unchanged drug; biliary/fecal excretion accounts for ~20%.
Category C
Category C
Antihistamine
Antihistamine
Diphenoxylate + Bumetanide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide."